Stocks in news: JSW Infra, Stanley Lifestyles, SAMHI Hotels, Bank Of Baroda, IREDA
Indicating that the company is still interested in the mega Tajpur deep sea port in West Bengal, JSW Infrastructure Ltd said that it remains open to re-evaluate its strategy for the project.
Domestic indices recorded gains and scaled new heights last week despite mixed signals from the global market, particularly regarding inflation concerns. In today's trade, shares of , , , , IREDA among others will be in focus due to various news developments.JSW Infrastructure
Indicating that the company is still interested in the mega Tajpur deep sea port in West Bengal, JSW Infrastructure Ltd said that it remains open to re-evaluate its strategy for the project.
Stanley Lifestyles
Leading investment and brokerage firm has picked up 3.7 lakh shares in Stanley Lifestyles for about Rs 16.7 crore, which debuted at the bourses on Friday.
Read more: Here's the trade setup for today's session
SAMHI Hotels
SAMHI Hotels witnessed some significant block deals on Friday where Morgan Stanley Asia Singapore Pte and Abu Dhabi Investment Authority (ADIA) bought shares worth nearly Rs 58 crore and Rs 21 crore, respectively.
IREDA
In its first quarter update IREDA said loans sanctioned stood at Rs 9,136 crore, while loan disbursements were up 67% to Rs 5,320 crore.
Signature Global
Signature Global has bagged sales worth Rs 2,700 crore for residential project Titanium SPR in Gurugram.
Spandana Spoorthy
Spandana Spoorthy has received a fresh request from the outgoing promoter (Padmaja Gangireddy) for reclassification from Promoter category to public category since the conditions relating to shareholding are now complied.
Zydus Life has partnered with Dr Reddy's to co-market Pertuzumab biosimilar for breast cancer treatment.
has advanced its net zero target for Scope-1 and Scope-2 GHG Emissions to 2035 from 2040.
Bank Of Baroda
The board of Bank Of Baroda will meet on July 5 to consider a capital plan for FY25 by way of raising funds through additional tier 1 and tier 2 debt capital instruments with an interchangeability option.
Orchid Pharma partnered with to launch antibiotic Cefepime-Tazobactam in India.
Source: Stocks-Markets-Economic Times
